MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT)

Clinical trials for MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT) explained in plain language.

Never miss a new study

Get alerted when new MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT) trials appear

Sign up with your email to follow new studies for MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New two-drug combo aims to control rare lymphoma

Disease control Recruiting now

This study is testing whether combining two existing drugs—zanubrutinib and rituximab—works better as a first treatment for MALT lymphoma, a type of slow-growing cancer that often starts in the stomach or other organs. Researchers will give the drug combination to 42 newly diagno…

Matched conditions: MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT)

Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT)

Get alerted when new MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT) trials appear

New two-drug combo aims to control rare lymphoma